Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05309980
Other study ID # CHUBX2020RE0273
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 1, 2021
Est. completion date April 15, 2022

Study information

Verified date March 2022
Source University Hospital, Bordeaux
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In this before-after monocenter study, the authors teste the hypothesis that the implementation of a dedicated shock team could improve the outcome of patients with refractory cardiogenic shock assisted by mechanical circulatory support.


Description:

Short Term Mechanical Circulatory Support (STMCS) are the last resort therapeutics when refractory cardiogenic shock occurs. Growing technical possibilities like impella make the right choice at the right time challenging. At Bordeaux University Hospital, we have gathered the main protagonists which are the surgeon, the interventional cardiologist,and the intensivist as a shock team in January 2013. From that time, diagnosis of refractory cardiogenic shock triggers a multidisciplinary meeting driven by a common algorithm. The objective of this study is to perform a before-after comparison between decision of STMCS for refractory cardiogenic shock without shock team from january 2007 to january 2013 and after implementation of the shock team from April 2013 to April 2019.


Recruitment information / eligibility

Status Completed
Enrollment 250
Est. completion date April 15, 2022
Est. primary completion date April 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of cardiogenic shock - >1 sign of refractory cardiogenic shock : Dobutamine >10µg/kg/mn, epinephrine>0.25µg/kg/mn or Milrinone > 0.5µg/kg/mn ; ScvO2<55% ; pO2/FiO2<100 - No major counter indication to short term mechanical circulatory support : SOFA score > 15, prolonged cardiac arrest, severe chronic disease, direct LVAD implantation or heart transplantation, counter indication for systemic anticoagulation Exclusion Criteria: - Age < 18years - Post cardiotomy cardiogenic shock - Implantation of Impella 2.5 alone - Implantation of Intra Aortic Balloon Pump alone

Study Design


Related Conditions & MeSH terms


Intervention

Other:
standard of care
retrospective study : standard of care

Locations

Country Name City State
France Bordeaux University Hospital Pessac

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Vital status Proportion of patients alive One year after short term mechanical circulatory support initiation
Secondary Vital status proportion of patients alive 30 days after short term mechanical circulatory support initiation
Secondary Vital status proportion of patients alive 3 months after short term mechanical circulatory support initiation
Secondary Vital status proportion of patients alive 6 months after short term mechanical circulatory support initiation
Secondary Lenght of stay Intensive Care Unit length of stay up to Intensive Care Unit discharge, an average of 15 days
Secondary Lenght of stay Hospital length of stay up to one year
Secondary Long term mechanical circulatory support proportion of patients bridged to long term mechanical circulatory support up to intensive care unit discharge, an average of 15 days
Secondary Heart transplantation proportion of patients bridged to heart transplantation up to intensive care unit discharge, an average of 15 days
Secondary Weaning from short term mechanical circulatory support proportion of patients sucessfully weaned from short term mechanical circulatory support up to seven days from weaning attempt
Secondary New renal replacement therapy proportion of patients needing renal replacement therapy up to intensive care unit discharge, an average of 15 days
Secondary Limb ischaemia proportion of patients with limb ischaemia through short term mechanical circulatory support weaning, an average of 6 days
Secondary Stroke proportion of patients with stroke through short term mechanical circulatory support weaning, an average of 6 days
Secondary Short term mechanical circulatory support duration Short term mechanical circulatory support duration through short term mechanical circulatory support weaning, an average of 6 days
Secondary Severe haemorrage proportion of patients with severe haemorrage (massive haemorrhage according to SFAR or use of Novoseven or rescue surgery for bleeding) through short term mechanical circulatory support weaning, an average of 6 days
Secondary Extra Corporeal Membrane Oxygenation circuit clotting proportion of patients in which Extra Corporeal Membrane Oxygenation circuit clotting occured through short term mechanical circulatory support weaning, an average of 6 days
Secondary Sepsis proportion of patients in which sepsis occured up to intensive care unit discharge, an average of 15 days
Secondary Vital status proportion of patients alive when bridged to long term mechanical circulatory device or when transplanted One year after short term mechanical circulatory support initiation
Secondary Vital status proportion of patients alive when bridged to long term mechanical circulatory device or when transplanted 30 days after short term mechanical circulatory support initiation
Secondary Vital status proportion of patients alive when bridged to long term mechanical circulatory device or when transplanted 3 months after short term mechanical circulatory support initiation
Secondary Vital status proportion of patients alive when bridged to long term mechanical circulatory device or when transplanted 6 months after short term mechanical circulatory support initiation
See also
  Status Clinical Trial Phase
Recruiting NCT03283995 - Hemodynamic Assessment in Cardiogenic Shock Regarding the Etiology
Active, not recruiting NCT04325035 - The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock Phase 2
Active, not recruiting NCT05100836 - SURPASS Impella 5.5 Study
Not yet recruiting NCT05106491 - Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients N/A
Completed NCT02301819 - ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock N/A
Completed NCT01367743 - Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock Phase 4
Recruiting NCT05728359 - Genomic Determinants of Outcome in Cardiogenic Shock
Recruiting NCT05699005 - Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO Phase 1
Not yet recruiting NCT06338345 - Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients N/A
Completed NCT03436641 - Microcirculation in Cardiogenic Shock
Recruiting NCT03313687 - SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK
Recruiting NCT05506449 - The RECOVER IV Trial N/A
Completed NCT04144660 - "Treatment Use of ECMO In Pregnancy or Peripartum Patient."
Completed NCT04548739 - Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
Recruiting NCT04141410 - Global Longitudinal Strain Assessment in Cardiogenic Shock During Sepsis
Not yet recruiting NCT05879276 - Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. Phase 3
Enrolling by invitation NCT05570864 - Score TO Predict SHOCK - STOP SHOCK
Completed NCT02591771 - Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock Phase 2
Terminated NCT02279979 - Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial N/A
Completed NCT01374867 - CardShock Study and Registry N/A